CLINICAL TRIALS PROFILE FOR NUTRACORT

All Clinical Trials for NUTRACORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	Roswell Park Cancer Institute	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.

Clinical Trial Conditions for NUTRACORT

Condition Name

Condition Name for NUTRACORT
Intervention	Trials
Acute Lymphoblastic Leukemia	2
Untreated Childhood Acute Lymphoblastic Leukemia	2
B Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for NUTRACORT
Intervention	Trials
Leukemia	4
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3
Leukemia, Lymphoid	3

Clinical Trial Locations for NUTRACORT

Trials by Country

Trials by Country for NUTRACORT
Location	Trials
United States	213
Canada	30
Australia	5
New Zealand	5
Puerto Rico	3

Trials by US State

Trials by US State for NUTRACORT
Location	Trials
Illinois	7
New York	6
Ohio	6
Minnesota	6
Massachusetts	6

Clinical Trial Progress for NUTRACORT

Clinical Trial Phase

Clinical Trial Phase for NUTRACORT
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for NUTRACORT
Clinical Trial Phase	Trials
Active, not recruiting	4
Recruiting	2
Terminated	1

Clinical Trial Sponsors for NUTRACORT

Sponsor Name

Sponsor Name for NUTRACORT
Sponsor	Trials
National Cancer Institute (NCI)	8
Children's Oncology Group	4
Roswell Park Cancer Institute	1

Sponsor Type

Sponsor Type for NUTRACORT
Sponsor	Trials
NIH	8
Other	8
Industry	1

Last updated: May 26, 2026

Nutracort clinical trials update, market analysis and projections: what’s in the pipeline, where revenue is headed, and which risks matter

Nutracort is not a sufficiently identifiable drug entity for a market and clinical-trials update. No drug dossier-level data can be reliably tied to the brand name alone, including active ingredient, formulation, dosage forms, trial identifiers, FDA/EMA status, labeled indications, or revenue base. Without a unambiguous product definition, it is not possible to produce a complete, accurate clinical-trials update and market projection.

What drug is “Nutracort” (active ingredient, dosage form, sponsor) and why does it block an update?

A brand-name-only request cannot be converted into enforceable intelligence. “Nutracort” is not mapped to a single active ingredient, regulatory submission, or trial registry record that would support an evidence-based pipeline review, exclusivity timeline, or forecast.

What is the clinical-trials update for Nutracort (completed, ongoing, planned)?

No registry-level update can be produced without a specific Nutracort identifier (active ingredient + strength + route + sponsor/trial ID). Clinical-trials updates require confirmation of:

• Trial registration numbers (NCT/EudraCT/ISRCTN)
• Active ingredient and comparator mapping
• Study phase, start/completion dates, enrollment targets
• Endpoints and results status
• Whether the program is in the US FDA pathway (IND/Phase 1-3), Europe (EMA), or other jurisdictions

What market data supports Nutracort’s forecast (sales baseline, geography, payer mix)?

Market projection requires a known reference product definition and commercialization history, including:

• Current sales and major markets (US/EU/ROW)
• Channel mix (retail vs specialty vs hospital)
• Pricing and reimbursement anchors
• Competitor class landscape and substitution risk
• Uptake curves and treated-patient population

A brand-only prompt does not allow any of these inputs to be sourced to the correct asset.

When does Nutracort lose exclusivity, and what generic/biosimilar entry risks exist?

Exclusivity timelines and entry risks require identification of:

• Reference listed drug (RLD) and Orange Book listings (US)
• Patents in-force and their expiration dates
• Exclusivity codes (Hatch-Waxman 30/60/5-year; 505(b)(2) exclusivities)
• Paragraph IV filings, settlements, and launch-trigger events
• If biologic, biosimilar reference product and interchangeability status

No enforceable exclusivity analysis can be performed without a verified product and its regulatory record.

What is Nutracort’s regulatory status (FDA approval, IND/CTA, labeling, exclusivity)?

A regulatory status update requires direct linkage to:

• FDA drug application type (NDA/505(b)(2)/ANDA/BLA)
• Approval date, label indications, boxed warnings (if any)
• Complete Response Letters, agency feedback, and major safety communications
• EMA marketing authorization status and CHMP timelines
• Orphan/accelerated/priority review designations (if applicable)

Brand-only identification prevents mapping to any of these.

What is the commercial outlook and revenue projection for Nutracort over 3–7 years?

A credible forecast requires a baseline sales anchor, treatment population, adoption constraints, and competition assumptions. None can be established without the correct Nutracort asset identity, including active ingredient, route, and indication.

Key Takeaways

• “Nutracort” is not a sufficiently specific drug identifier to support a clinical trials update or market projections.
• Pipeline, exclusivity, regulatory status, and revenue forecasting cannot be produced without a unique product definition tied to regulatory and trial registries.

FAQs

1. How do I confirm the correct “Nutracort” active ingredient and regulatory record before forecasting market adoption?
2. What clinical trial registries should be checked for Nutracort once the active ingredient and trial ID are identified?
3. How do Orange Book and patent expiration schedules translate into generic entry risk scenarios?
4. What KPIs drive a 3–7 year revenue model for a new drug launch versus a mature brand?
5. What competitor benchmarks should be used for class-level forecasting of Nutracort’s treated-patient share?

References

1. FDA. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. (Database).
2. ClinicalTrials.gov. (Database).
3. EMA. European public assessment reports and EPARs. (Database).